Lacrimal Gland Marginal Zone Lymphoma: Regression after Treatment of Chronic Hepatitis C Virus Infection: Case Report and Review of the Literature

• Published in: Internal Medicine Vol. 52; no. 23; pp. 2615 - 2618
• Main Authors: Coskun, Adil, Yukselen, Ozden, Yukselen, Vahit, Karaoglu, A. Onder
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Internal Medicine 01-01-2013
• Subjects: Adult; Antiviral Agents - therapeutic use; Eye Neoplasms - complications; Eye Neoplasms - diagnostic imaging; Eye Neoplasms - pathology; Female; Hepatitis C virus; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; Humans; Interferon alpha-2; Interferon-alpha - therapeutic use; Lacrimal Apparatus - diagnostic imaging; lacrimal gland lymphoma; Lymphoma, B-Cell, Marginal Zone - complications; Lymphoma, B-Cell, Marginal Zone - diagnostic imaging; Lymphoma, B-Cell, Marginal Zone - pathology; marginal zone lymphoma; pegylated interferon; Polyethylene Glycols - therapeutic use; Recombinant Proteins - therapeutic use; Remission Induction; Ribavirin - therapeutic use; Tomography, X-Ray Computed
• ISSN: 0918-2918; 1349-7235
• DOI: 10.2169/internalmedicine.52.0450

A 43-year-old woman was first admitted to the ophthalmology clinic with the complaint of a mass compressing the right eye. Based on clinical and laboratory examinations she was diagnosed as having marginal zone lymphoma (MZL) of the right lacrimal gland in addition to hepatitis C virus (HCV) infection. After the treatment for HCV infection with pegylated interferon plus ribavirin, a radiographic response of the MZL was obtained; she remains in remission through thirty months of clinical follow-up. In this case, the treatment of HCV infection led to regression of MZL suggesting the necessity of testing for HCV infection and treatment of the HCV infection should be highly considered in all HCV-positive patients with MZL's.